DK1768677T3 - Nucleinsyrer til behandling af HMGB1-relaterede patologier - Google Patents

Nucleinsyrer til behandling af HMGB1-relaterede patologier

Info

Publication number
DK1768677T3
DK1768677T3 DK05773148T DK05773148T DK1768677T3 DK 1768677 T3 DK1768677 T3 DK 1768677T3 DK 05773148 T DK05773148 T DK 05773148T DK 05773148 T DK05773148 T DK 05773148T DK 1768677 T3 DK1768677 T3 DK 1768677T3
Authority
DK
Denmark
Prior art keywords
treatment
hmgb1
nucleic acids
related pathologies
nucleic acid
Prior art date
Application number
DK05773148T
Other languages
Danish (da)
English (en)
Inventor
Domenico G Barone
Marco E Bianchi
Enrico M Bucci
Silvano Fumero
Margherita Valente
Roberto Sapio
Domenica Musumeci
Original Assignee
Creabilis Therapeutics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1768677(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics Spa filed Critical Creabilis Therapeutics Spa
Application granted granted Critical
Publication of DK1768677T3 publication Critical patent/DK1768677T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05773148T 2004-07-02 2005-07-04 Nucleinsyrer til behandling af HMGB1-relaterede patologier DK1768677T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58467804P 2004-07-02 2004-07-02
US64658605P 2005-01-26 2005-01-26
PCT/EP2005/007198 WO2006002971A2 (en) 2004-07-02 2005-07-04 Nucleic acids for the treatment of hmgb1-related pathologies

Publications (1)

Publication Number Publication Date
DK1768677T3 true DK1768677T3 (da) 2008-10-20

Family

ID=35106975

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05773148T DK1768677T3 (da) 2004-07-02 2005-07-04 Nucleinsyrer til behandling af HMGB1-relaterede patologier

Country Status (14)

Country Link
US (1) US20080305073A1 (enExample)
EP (1) EP1768677B1 (enExample)
JP (1) JP2008504335A (enExample)
AT (1) ATE399014T1 (enExample)
AU (1) AU2005259381A1 (enExample)
BR (1) BRPI0512944A (enExample)
CA (1) CA2572519A1 (enExample)
DE (1) DE602005007746D1 (enExample)
DK (1) DK1768677T3 (enExample)
ES (1) ES2306195T3 (enExample)
IL (1) IL179828A0 (enExample)
PL (1) PL1768677T3 (enExample)
PT (1) PT1768677E (enExample)
WO (1) WO2006002971A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001559A (es) 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
KR20090087483A (ko) * 2006-11-17 2009-08-17 클리니컬 진 네트웍스 아베 유전자 ｇｙｐｃ, ａｇｐａｔ3, ａｇｌ, ｐｖｒｌ2, ｈｍｇｂ3, ｈｓｄｌ2 및/또는 ｌｄｂ2를 포함하는 스크리닝 및 치료방법
CN101589309A (zh) * 2006-11-17 2009-11-25 临床基因网络公司 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法
WO2009140676A2 (en) * 2008-05-16 2009-11-19 Immune Disease Institute, Inc. Compositions and methods for inhibition of retroviruses
US8710021B2 (en) 2008-06-11 2014-04-29 Bionucleon S.R.L. Inhibition of HRP-3 using modified oligonucleotides
JP5710482B2 (ja) 2008-09-11 2015-04-30 アンスティテュ・パストゥール Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
BRPI0923583A2 (pt) 2008-12-22 2018-10-09 Creabilis S A síntese de conjugados de polímeros de compostos de indocarbzol.
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
JP5686814B2 (ja) 2010-09-17 2015-03-18 独立行政法人科学技術振興機構 Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
WO2013116590A1 (en) * 2012-02-01 2013-08-08 George Miller Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP6624542B2 (ja) * 2015-02-05 2019-12-25 国立大学法人広島大学 ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175315A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates of staurosporine derivatives having reduced exposure
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175301A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugate of montesanib with reduced exposure
WO2018208369A1 (en) 2017-05-10 2018-11-15 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
CN111304202B (zh) * 2020-02-26 2023-03-28 西安交通大学 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用
CN114957440A (zh) * 2022-05-26 2022-08-30 江苏大学 一种重组HMGB1 A Box蛋白及其获取方法与应用
JP2025521607A (ja) * 2022-06-23 2025-07-10 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン アルツハイマー病を含むａｐｏｅ４－関連タウオパチーの治療のためのｈｍｇｂ１阻害剤
CN114807150B (zh) * 2022-06-28 2022-10-14 中国科学院基础医学与肿瘤研究所(筹) 靶向和拮抗hmgb1分子的核酸适体
WO2024020320A2 (en) 2022-07-19 2024-01-25 Rampart Bioscience, Inc. Non-immunogenic circular, non-viral dna vectors
CN115774004B (zh) * 2022-08-19 2024-07-05 四川大学华西医院 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009158A1 (en) * 1992-10-14 1994-04-28 University Research Corporation Method for selecting nucleic acids on the basis of structure
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
NZ540067A (en) * 2002-11-20 2007-05-31 Critical Therapeutics Inc A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB

Also Published As

Publication number Publication date
WO2006002971A3 (en) 2006-04-20
CA2572519A1 (en) 2006-01-12
BRPI0512944A (pt) 2008-04-15
JP2008504335A (ja) 2008-02-14
AU2005259381A1 (en) 2006-01-12
ES2306195T3 (es) 2008-11-01
EP1768677B1 (en) 2008-06-25
DE602005007746D1 (de) 2008-08-07
IL179828A0 (en) 2008-03-20
PL1768677T3 (pl) 2009-01-30
EP1768677A2 (en) 2007-04-04
WO2006002971A2 (en) 2006-01-12
ATE399014T1 (de) 2008-07-15
PT1768677E (pt) 2008-10-06
US20080305073A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
DK1768677T3 (da) Nucleinsyrer til behandling af HMGB1-relaterede patologier
EP2097111A4 (en) HETERODIMERS OF GLUTAMIC ACID
DE502005009604D1 (de) Verfahren zur herstellung von ameisensäure
DE602006016150D1 (de) Vorbeugung von krankheiten bei kaiserschnitt-babies
DK2066684T3 (da) 5´-Modificerede bicycliske nukleinsyreanaloge
EP1934354A4 (en) METHODS FOR PRODUCING HYBRID SEED
ATE451402T1 (de) Methacrylatharze zur herstellung von fahrbahnmarkierungen
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
DK2135949T3 (da) MCP-1-bindende nukleinsyrer
DE602005017027D1 (de) Verfahren zur enzymatischen herstellung von (s)-3-cyano-5-methylhexansäure
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
MX373170B (es) Variantes de la familia il-1.
DE602006010302D1 (de) Verfahren zur Herstellung von 5-methyl-2-furfural
DE602006006009D1 (de) Methode zur Herstellung von Acrylsäure
EP1960416A4 (en) PURIFICATION PROCESS FOR CHENODEOXYCHOLIC ACID
DE602006009562D1 (de) Verfahren zur herstellung von ferrisuccinylcasein
EP1914220A4 (en) PROCESS FOR THE PRODUCTION OF 2-HYDROXY ESTERS
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
EP2368989A4 (en) OLOGORIBONUCLEOTIDE OR PEPTIDE NUCLEIC ACID CAPABLE OF INHIBITING HEPATITIS C VIRUS ACTIVITY
ATE509945T1 (de) Chirale mit phosphonsäureester- oder phosphonsäure- substituierte verbindungen
DE602007001037D1 (de) Verfahren zur Herstellung von Acrylsäure
EP1757685A4 (en) MODIFIED ETHYLENEDIAMIN N, N'-DIBERNIC ACID: ETHYLENEDIAMINE LYASE